Search Results - "Aviles, Art"

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    CLL-1-Targeted Allogeneic CAR-T Cells Exhibit High on-Target Specificity and Potent Cytotoxicity in Preclinical Models of Acute Myeloid Leukemia

    CLL-1-Targeted Allogeneic CAR-T Cells Exhibit High on-Target Specificity and Potent Cytotoxicity in Preclinical Models of Acute Myeloid Leukemia by Francica, Brian, Garner, Elizabeth, Namburi, Sai, Colgan, Cian, Fowler, Tristan, Mutha, Devin, Aviles, Art, Stanaway, Morena, Guo, Raymond, An, Zili, Kelly, Erin, Degagne, Emilie, Kwong, George, Edwards, Leslie, Jakes, Emma, Shaw, McKay, Schilling, Benjamin, Huynh, Jeremy, Luu, Ricky, Sidorov, Max, Mousali, Rhonda, Otsmaa, Mikk, Lauer, Peter, Skoble, Justin, Kanner, Steven

    Published in Blood (02-11-2023)
    “…Background: CLL-1 is a compelling therapeutic target for acute myeloid leukemia (AML) as it is highly expressed on AML tumor cells and leukemic stem cells, but…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Abstract 6323: Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent toxicity in acute myeloid leukemia (AML) xenograft models

    Abstract 6323: Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent toxicity in acute myeloid leukemia (AML) xenograft models by Francica, Brian, Garner, Elizabeth, Namburi, Sai, Colgan, Cian, Fowler, Tristan, Mutha, Devin, Aviles, Art, Stanaway, Morena, Guo, Raymond, An, Zili, Kelly, Erin, Degagne, Emilie, Kwong, George, Edwards, Leslie, Jakes, Emma, Shaw, McKay, Schilling, Benjamin, Huynh, Jeremy, Luu, Ricky, Sidorov, Max, Mousali, Rhonda, Otsmaa, Mikk, Lauer, Peter, Skoble, Justin, Kanner, Steven

    Published in Cancer research (Chicago, Ill.) (22-03-2024)
    “…Abstract Background: CLL-1 is a compelling therapeutic target for AML as it is highly expressed on AML tumor cells and leukemic stem cells but is not expressed…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Abstract 3201: CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia

    Abstract 3201: CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia by Garner, Elizabeth, Kelly, Erin, Namburi, Sai, Colgan, Cian, Fowler, Tristan, Mutha, Devin, Aviles, Art, Stanaway, Morena, Guo, Raymond, An, Zili, Degagne, Emilie, Kwong, George, Edwards, Leslie, Jakes, Emma, Shaw, McKay, Schilling, Benjamin, Huynh, Jeremy, Luu, Ricky, Sidorov, Max, Mousali, Rhonda, Otsmaa, Mikk, Skoble, Justin, Kanner, Steven

    Published in Cancer research (Chicago, Ill.) (04-04-2023)
    “…Abstract Background: CB-012 is an allogeneic anti-CLL-1 CAR-T cell therapy in development for evaluation in relapsed or refractory acute myeloid leukemia (r/r…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: